Intrexon Corp (XON) : Belmont Global Advisors reduced its stake in Intrexon Corp by 26.24% during the most recent quarter end. The investment management company now holds a total of 280,550 shares of Intrexon Corp which is valued at $7,931,149 after selling 99,800 shares in Intrexon Corp , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Intrexon Corp makes up approximately 14.38% of Belmont Global Advisors’s portfolio.
Other Hedge Funds, Including , Aqr Capital Management reduced its stake in XON by selling 340,770 shares or 43.01% in the most recent quarter. The Hedge Fund company now holds 451,611 shares of XON which is valued at $12,767,043. Intrexon Corp makes up approx 0.02% of Aqr Capital Management’s portfolio. Quantitative Investment Management sold out all of its stake in XON during the most recent quarter. The investment firm sold 27,300 shares of XON which is valued $775,047.Emerald Advisers Incpa reduced its stake in XON by selling 62,436 shares or 16.2% in the most recent quarter. The Hedge Fund company now holds 322,897 shares of XON which is valued at $8,178,981. Intrexon Corp makes up approx 0.37% of Emerald Advisers Incpa’s portfolio.
Intrexon Corp opened for trading at $25.01 and hit $25.55 on the upside on Thursday, eventually ending the session at $25.29, with a gain of 0.20% or 0.05 points. The heightened volatility saw the trading volume jump to 10,50,463 shares. Company has a market cap of $2,992 M.
On the company’s financial health, Intrexon Corp reported $-0.42 EPS for the quarter, missing the analyst consensus estimate by $ -0.14 based on the information available during the earnings call on Aug 9, 2016. Analyst had a consensus of $-0.28. The company had revenue of $52.50 million for the quarter, compared to analysts expectations of $53.78 million. The company’s revenue was up 17.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.37 EPS.
Intrexon Corporation is engaged in the field of synthetic biology. The Company designs builds and regulates gene programs which are Deoxyribonucleic Acid (DNA) sequences that consist of genetic components. The Companys synthetic biology capabilities include the ability to control the amount location and modification of biological molecules to control the function and output of living cells. The Companys technologies include UltraVector RheoSwitch Therapeutic System Cell Systems Informatics Protein Engineering AttSite Recombinases LEAP (Laser Enabled Analysis and Processing) Antibody Discovery Neurospora & Agaricus Platforms Endometrial Regenerative Cells ActoBiotics Porcine Research Models and BeyondBio. The Company serves various markets including health food energy environment and consumer. The Company has five operating divisions: Human Therapeutics Synthetic Immunology Animal Sciences Agricultural Biotech and Industrial Products.